Results 11 to 20 of about 23,850 (163)

A retrospective study to assess the risk of bladder cancer in type-2 diabetic patients treated with pioglitazone

Perspectives in Clinical Research, 2021
Introduction: Pioglitazone has been a cornerstone of oral hypoglycemic therapy. Concerns have been raised about its association with urinary bladder cancer.
Prabhat Agrawal, Apoorva Jain, Ashish Gautam, Ashwini Kumar Nigam, Nikhil Pursnani, Maaz Farooqui   +5 more
doaj   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis. [PDF]

Diabetes Obes Metab
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Silverii GA, Velardi V, Marinelli C, Lax A, Monami M, Mannucci E.   +5 more
europepmc   +2 more sources

Probiotics ameliorate pioglitazone-associated bone loss in diabetic rats

Diabetology & Metabolic Syndrome, 2020
Background Pioglitazone, as a PPAR gamma agonist, is used for the management of type 2 diabetes mellitus. Nevertheless, evidence showed that the therapeutic modulation of PPAR gamma activity using pioglitazone might be linked with bone mass reduction and
Ahmad Gholami, Mohammad Hossein Dabbaghmanesh, Younes Ghasemi, Pedram Talezadeh, Farhad Koohpeyma, Nima Montazeri-Najafabady   +5 more
doaj   +1 more source

Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome

Journal of Pharmacological Sciences, 2019
Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS).
Tsukasa Nozu, Saori Miyagishi, Rintaro Nozu, Kaoru Takakusaki, Toshikatsu Okumura   +4 more
doaj   +1 more source

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study

Cardiovascular Diabetology, 2020
Background Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare.
Yi-Chih Hung, Lu-Ting Chiu, Hung-Yu Huang, Da-Tian Bau   +3 more
doaj   +1 more source

Effects of Pioglitazone on Nonalcoholic Fatty Liver Disease in the Absence of Constitutive Androstane Receptor Expression

PPAR Research, 2018
Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD.
Hwa Young Ahn, Hwan Hee Kim, Ji-Yeon Hwang, Changhun Park, Bo Youn Cho, Young Joo Park   +5 more
doaj   +1 more source

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

PLoS ONE, 2018
BackgroundChoices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects.
Bancha Satirapoj, Khanin Watanakijthavonkul, Ouppatham Supasyndh   +2 more
doaj   +1 more source

Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin

Scientific Reports, 2023
Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM).
Hsin-Chung Lin, Chi-Hsiang Chung, Lih-Chyang Chen, Jui-Yang Wang, Chien-Chou Chen, Kuo-Yang Huang, Ming-Hang Tsai, Wu-Chien Chien, Hsin-An Lin   +8 more
doaj   +1 more source

Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells

Journal of Lipid Research, 2010
Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and ...
Lin-Hua Zhang, Vaijinath S. Kamanna, Shobha H. Ganji, Xi-Ming Xiong, Moti L. Kashyap   +4 more
doaj   +1 more source

Pioglitazone Improves Mitochondrial Function in the Remnant Kidney and Protects against Renal Fibrosis in 5/6 Nephrectomized Rats

Frontiers in Pharmacology, 2017
Pioglitazone is a type of peroxisome proliferator-activated receptor γ (PPARγ) agonist and has been demonstrated to be effective in chronic kidney diseases (CKD) treatment.
Li Sun, Quan Yuan, Tianhua Xu, Li Yao, Jiangmin Feng, Jianfei Ma, Lining Wang, Changlong Lu, Danan Wang   +8 more
doaj   +1 more source